Korro Bio is trading at $10.35, up 6.05%, with no company-specific catalyst identified in available coverage.
- No company announcement dated October 7 surfaced in the search; coverage centers on October 5’s first-cohort dosing in the KRRO-121 Phase 1/2 trial.
- Analysts’ October 6 Buy-rating reiterations were not linked to the October 7 intraday move.
- Biotech fell 2.50% and major U.S. indexes were lower; broader weakness does not explain the rise.